Moleculin Biotech Inc. has appointed Adriano Treve as a Strategic Advisor for partnerships. With over 40 years of experience at Roche, including executive roles in various regions, Treve will assist in advancing Moleculin's strategic partnerships as they progress in their Phase 2B/3 clinical trial of Annamycin for acute myeloid leukemia. This move is expected to enhance the company's strategic positioning and partnership opportunities.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.